166 related articles for article (PubMed ID: 21557639)
1. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer.
Mirandola L; J Cannon M; Cobos E; Bernardini G; Jenkins MR; Kast WM; Chiriva-Internati M
Int Rev Immunol; 2011; 30(2-3):127-37. PubMed ID: 21557639
[TBL] [Abstract][Full Text] [Related]
2. Sperm protein 17: clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond.
Chiriva-Internati M
Int Rev Immunol; 2011; 30(2-3):138-49. PubMed ID: 21557640
[TBL] [Abstract][Full Text] [Related]
3. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
4. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
5. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations.
Dakshinamurthy AG; Ramesar R; Goldberg P; Blackburn JM
Biotechnol J; 2008 Nov; 3(11):1417-23. PubMed ID: 18956367
[TBL] [Abstract][Full Text] [Related]
6. Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients.
Siliņa K; Zayakin P; Kalniņa Z; Ivanova L; Meistere I; Endzeliņš E; Abols A; Stengrēvics A; Leja M; Ducena K; Kozirovskis V; Linē A
J Immunother; 2011 Jan; 34(1):28-44. PubMed ID: 21150711
[TBL] [Abstract][Full Text] [Related]
7. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
Ulbright TM
Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
[TBL] [Abstract][Full Text] [Related]
8. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
[TBL] [Abstract][Full Text] [Related]
9. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers.
Williams TI; Toups KL; Saggese DA; Kalli KR; Cliby WA; Muddiman DC
J Proteome Res; 2007 Aug; 6(8):2936-62. PubMed ID: 17583933
[TBL] [Abstract][Full Text] [Related]
10. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?
Chiriva-Internati M; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):67-70. PubMed ID: 21557634
[TBL] [Abstract][Full Text] [Related]
11. Discovery and application of protein biomarkers for ovarian cancer.
Gagnon A; Ye B
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
[TBL] [Abstract][Full Text] [Related]
12. Proteomics and biomarkers for ovarian cancer diagnosis.
Zhang B; Barekati Z; Kohler C; Radpour R; Asadollahi R; Holzgreve W; Zhong XY
Ann Clin Lab Sci; 2010; 40(3):218-25. PubMed ID: 20689132
[TBL] [Abstract][Full Text] [Related]
13. Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene.
Jäger D; Stockert E; Scanlan MJ; Güre AO; Jäger E; Knuth A; Old LJ; Chen YT
Cancer Res; 1999 Dec; 59(24):6197-204. PubMed ID: 10626813
[TBL] [Abstract][Full Text] [Related]
14. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells.
Xu FJ; Yu YH; Li BY; Moradi M; Elg S; Lane C; Carson L; Ramakrishnan S
Cancer Res; 1991 Aug; 51(15):4012-9. PubMed ID: 1855217
[TBL] [Abstract][Full Text] [Related]
15. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer.
Ye B; Gagnon A; Mok SC
Expert Rev Proteomics; 2007 Feb; 4(1):121-31. PubMed ID: 17288520
[TBL] [Abstract][Full Text] [Related]
16. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D
Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797
[TBL] [Abstract][Full Text] [Related]
17. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens.
Almeida LG; Sakabe NJ; deOliveira AR; Silva MC; Mundstein AS; Cohen T; Chen YT; Chua R; Gurung S; Gnjatic S; Jungbluth AA; Caballero OL; Bairoch A; Kiesler E; White SL; Simpson AJ; Old LJ; Camargo AA; Vasconcelos AT
Nucleic Acids Res; 2009 Jan; 37(Database issue):D816-9. PubMed ID: 18838390
[TBL] [Abstract][Full Text] [Related]
18. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
[TBL] [Abstract][Full Text] [Related]
19. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer.
Colombo N; Van Gorp T; Parma G; Amant F; Gatta G; Sessa C; Vergote I
Crit Rev Oncol Hematol; 2006 Nov; 60(2):159-79. PubMed ID: 17018256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
